Jame Abraham, MD, on Breast Cancer: Expert Perspective on the MONARCH 2 Trial

2017 ASCO Annual Meeting
Tweet this page

Jame Abraham, MD, of the Cleveland Clinic, gives his views on findings on abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. (Abstract 1000)

Advertisement

Advertisement



Advertisement